Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 2
2014 3
2015 6
2016 1
2017 2
2018 5
2019 3
2020 1
2021 5
2022 1
2023 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, Dubroja N, Shankar G, Bosisio FM, Roussel E, Verbiest A, Finotello F, Ausserhofer M, Lambrechts D, Boeckx B, Wozniak A, Boon L, Kerkhofs J, Zucman-Rossi J, Albersen M, Baldewijns M, Beuselinck B, Garg AD. Kinget L, et al. Among authors: zucman rossi j, beuselinck b. Nat Med. 2024 Jun;30(6):1667-1679. doi: 10.1038/s41591-024-02978-9. Epub 2024 May 21. Nat Med. 2024. PMID: 38773341
Molecular subtypes and prognosis in RCC.
Beuselinck B, Fridman WH, Zucman-Rossi J. Beuselinck B, et al. Among authors: zucman rossi j. Aging (Albany NY). 2015 Apr;7(4):219-20. doi: 10.18632/aging.100736. Aging (Albany NY). 2015. PMID: 25885644 Free PMC article. No abstract available.
Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.
Beulque Y, Kinget L, Roussel E, Mobaraki S, Laenen A, Debruyne PR, Van Herck Y, Baldewijns M, Wozniak A, Garg AD, Zucman-Rossi J, Couchy G, Albersen M, De Wever L, Haaker L, Beuselinck B. Beulque Y, et al. Among authors: zucman rossi j, beuselinck b. Acta Oncol. 2024 Aug 11;63:658-668. doi: 10.2340/1651-226X.2024.40390. Acta Oncol. 2024. PMID: 39129249 Free PMC article.
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
Santos M, Lanillos J, Caleiras E, Valdivia C, Roldan-Romero JM, Laínez N, Puente J, Beuselinck B, Oudard S, Zucman-Rossi J, Navarro P, Robledo M, Castellano D, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Among authors: zucman rossi j, beuselinck b. Am J Cancer Res. 2023 May 15;13(5):2116-2125. eCollection 2023. Am J Cancer Res. 2023. PMID: 37293154 Free PMC article.
Author Correction: A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L, Naulaerts S, Govaerts J, Vanmeerbeek I, Sprooten J, Laureano RS, Dubroja N, Shankar G, Bosisio FM, Roussel E, Verbiest A, Finotello F, Ausserhofer M, Lambrechts D, Boeckx B, Wozniak A, Boon L, Kerkhofs J, Zucman-Rossi J, Albersen M, Baldewijns M, Beuselinck B, Garg AD. Kinget L, et al. Among authors: zucman rossi j, beuselinck b. Nat Med. 2024 Aug;30(8):2375-2376. doi: 10.1038/s41591-024-03174-5. Nat Med. 2024. PMID: 39009782 No abstract available.
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reyniès A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B. Verbiest A, et al. Among authors: zucman rossi j, beuselinck b. Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612. doi: 10.1016/j.clgc.2017.10.017. Epub 2017 Nov 7. Clin Genitourin Cancer. 2018. PMID: 29239846
Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications.
Roussel E, Kinget L, Verbiest A, Boeckx B, Zucman-Rossi J, Couchy G, Caruso S, Baldewijns M, Joniau S, Van Poppel H, Lambrechts D, Albersen M, Beuselinck B. Roussel E, et al. Among authors: zucman rossi j, beuselinck b. Acta Oncol. 2021 Nov;60(11):1499-1506. doi: 10.1080/0284186X.2021.1962971. Epub 2021 Aug 27. Acta Oncol. 2021. PMID: 34448678
Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).
Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH. Becht E, et al. Among authors: zucman rossi j, beuselinck b. Oncoimmunology. 2015 Aug 7;4(12):e1049804. doi: 10.1080/2162402X.2015.1049804. eCollection 2015 Dec. Oncoimmunology. 2015. PMID: 26587318 Free PMC article.
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.
Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B. Verbiest A, et al. Among authors: zucman rossi j, beuselinck b. Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25. Clin Genitourin Cancer. 2019. PMID: 31229459
30 results